These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38713052)
101. EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications. Voutsadakis IA Curr Issues Mol Biol; 2023 Jul; 45(7):6040-6054. PubMed ID: 37504297 [TBL] [Abstract][Full Text] [Related]
102. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726 [TBL] [Abstract][Full Text] [Related]
103. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Voutsadakis IA Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317 [No Abstract] [Full Text] [Related]
104. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer. Nishijima TF; Kardos J; Chai S; Smith CC; Bortone DS; Selitsky SR; Parker JS; Sanoff HK; Lee MS; Vincent BG JCO Precis Oncol; 2017 Nov; 1():1-10. PubMed ID: 35172495 [TBL] [Abstract][Full Text] [Related]
105. Nuclear staining of claudin-18 is a new immunohistochemical marker for diagnosing intramucosal well-differentiated gastric adenocarcinoma. Takahashi Y; Tsutsumi Y; Takeuchi C; Shiogama K; Mizutani Y; Inada KI; Yamamichi N; Koike K Pathol Int; 2020 Sep; 70(9):644-652. PubMed ID: 32623829 [TBL] [Abstract][Full Text] [Related]
107. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Voutsadakis IA; Digklia A Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358 [TBL] [Abstract][Full Text] [Related]
108. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. Voutsadakis IA Crit Rev Oncol Hematol; 2023 Jun; 186():103987. PubMed ID: 37059275 [TBL] [Abstract][Full Text] [Related]
110. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Kyuno D; Takasawa A; Takasawa K; Ono Y; Aoyama T; Magara K; Nakamori Y; Takemasa I; Osanai M Tissue Barriers; 2022 Jan; 10(1):1967080. PubMed ID: 34486479 [TBL] [Abstract][Full Text] [Related]
111. The role of claudin-4 in the development of gastric cancer. Liu W; Li M Scand J Gastroenterol; 2020 Sep; 55(9):1072-1078. PubMed ID: 32715822 [TBL] [Abstract][Full Text] [Related]
112. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies. Voutsadakis IA Tissue Barriers; 2024 May; ():2348852. PubMed ID: 38713052 [TBL] [Abstract][Full Text] [Related]